Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Female AYAs Experience Financial Hardship Associated with Cancer-Related Employment Disruption

October 20, 2020
By Hannah Slater
Article

This study indicated that the financial hardship associated with cancer-related employment disruption among female adolescent and young adults can be sizable, suggesting a need for interventions to aid this patient population.

The financial hardship associated with cancer-related employment disruption among female adolescent and young adults (AYAs) can be sizable according to a study published in Cancer, especially among women diagnosed at a younger age, Hispanic women, and those with caregiving responsibilities.1

Given these findings, assistance returning to work following treatment as well as workplace accommodation policies present as important opportunities to lessen financial hardship and improve cancer survivorship care among this vulnerable patient population.

“Our study addresses the burden of employment disruption and financial hardship among young women with cancer—a group who may be at particular risk for poor financial outcomes after cancer given their age and gender,” Clare Meernik, MPH, of the University of North Carolina at Chapel Hill, said in a press release.2 “Our findings highlight the need for effective interventions to promote job maintenance and transition back to the workforce after cancer treatment, as well as increased workplace accommodations and benefits, to improve cancer outcomes for young women.”

Responses to an online survey were collected from AYA cancer survivors identified through the North Carolina Central Cancer Registry and the Kaiser Permanente Northern/Southern California tumor registries. Of note, disrupted unemployment was defined as reducing hours, taking temporary leave, or stopping work entirely due to cancer. Financial hardship was defined as material conditions or psychological distress which developed because of cancer.

Of 1328 women eligible for study who were employed at the time of their diagnosis, women were a median age of 34 years at the time of diagnosis and 7 years from diagnosis at the time of the survey. Overall, approximately 32% of the cohort experienced employment disruption.

A considerable percentage of the patients studied reported financial hardship related to material conditions (27%) or psychological distress (50%). Further, in adjusted analyses, women with disrupted employment experienced a 17% higher burden of material conditions (95% CI, 10%-23%) and an 8% higher burden of psychological distress (95% CI, 1%-16%) compared with those who did not experience a disruption.

“The relationship between employment disruption and material conditions was particularly pronounced among women diagnosed at a younger age (aged <35 years) and Hispanic women, whereas the relationship between employment disruption and psychological distress was stronger among women aged 30 to 34 years, those who were 6 to 9 years after their diagnosis, and those acting as caregivers,” the authors added. “The findings of the current study also highlighted the severity of material conditions related to employment disruption: 24% of women with disruption borrowed or went into debt of at least $10,000 and 9% borrowed or went into debt of at least $25,000 compared with 9% and 2.5%, respectively, among women with no disruption.”

According to the investigators, the development of survivorship care interventions that promote self-management and assist with transitioning back to or remaining in the workforce following a diagnosis of cancer may help to alleviate or prevent the effects of employment disruption on financial hardship. Moreover, the effects of cancer-related employment disruption could also be diminished or prevented altogether with the implementation of more flexible work accommodations and sick leave policies.

Moving forward, researchers suggested future studies that examine employment and financial outcomes among AYA cancer survivors would benefit by assessing more detailed information regarding factors such as dependent status at the time of diagnosis, household income, health insurance throughout treatment, employer-provided sick leave benefits and other disability insurance, demands of unpaid caregiving roles, and a variety of indicators of financial hardship. Information such as this could be used to inform potential targets of intervention.

References:

1. Meernik C, Kirchhoff AC, Anderson C, et al. Material and Psychological Financial Hardship Related to Employment Disruption Among Female Adolescent and Young Adult Cancer Survivors. Cancer. doi: 10.1002/cncr.33190

2. Study Examines Cancer’s Effects on Young Women’s Employment and Finances [news release]. Published October 12, 2020. Accessed October 13, 2020. https://newsroom.wiley.com/press-releases/press-release-details/2020/Study-Examines-Cancers-Effects-on-Young-Womens-Employment-and-Finances/default.aspx

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content
Advertisement

EPCORE NHL-2 Trials Yield High Responses With /R-mini-CHOP in First Line DLBCL

EPCORE NHL-2 Trials Yield High Responses With /R-mini-CHOP in First Line DLBCL

Kristie L. Kahl
December 7th 2025
Article

“We can conclude that in combination with dose-attenuated chemotherapy, [epcoritamab] may have a role in the treatment of patients with historically poor outcomes,” said Chan Cheah, MD.


Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.


Increased Dose of Axatilimab Noted as Tolerable in cGVHD

Increased Dose of Axatilimab Noted as Tolerable in cGVHD

Kristie L. Kahl
December 6th 2025
Article

“Overall, these findings support the safety and feasibility of axatilimab at a dose of 0.6 mg/kg monthly,” said Nosha Farhadfar, MD.


Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.


Early Efficacy Highlighted With  Odronextamab/CHOP in Untreated DLBCL

Early Efficacy Highlighted With Odronextamab/CHOP in Untreated DLBCL

Silas Inman
December 6th 2025
Article

An ORR of 100% was noted in the 160 mg odronextamab/CHOP cohort in untreated DLBCL.


The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction.

Cilta-Cel Exhibits Long-Term Survival in Standard-Risk R/R Multiple Myeloma

Chris Ryan
December 6th 2025
Article

The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction.

Related Content
Advertisement

EPCORE NHL-2 Trials Yield High Responses With /R-mini-CHOP in First Line DLBCL

EPCORE NHL-2 Trials Yield High Responses With /R-mini-CHOP in First Line DLBCL

Kristie L. Kahl
December 7th 2025
Article

“We can conclude that in combination with dose-attenuated chemotherapy, [epcoritamab] may have a role in the treatment of patients with historically poor outcomes,” said Chan Cheah, MD.


Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.


Increased Dose of Axatilimab Noted as Tolerable in cGVHD

Increased Dose of Axatilimab Noted as Tolerable in cGVHD

Kristie L. Kahl
December 6th 2025
Article

“Overall, these findings support the safety and feasibility of axatilimab at a dose of 0.6 mg/kg monthly,” said Nosha Farhadfar, MD.


Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.


Early Efficacy Highlighted With  Odronextamab/CHOP in Untreated DLBCL

Early Efficacy Highlighted With Odronextamab/CHOP in Untreated DLBCL

Silas Inman
December 6th 2025
Article

An ORR of 100% was noted in the 160 mg odronextamab/CHOP cohort in untreated DLBCL.


The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction.

Cilta-Cel Exhibits Long-Term Survival in Standard-Risk R/R Multiple Myeloma

Chris Ryan
December 6th 2025
Article

The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.